Singapore, August 27, 2007: GE Healthcare has received an approval from the US Food and Drug Administration (FDA) for its new mobile mammography product that will improve access to breast cancer screening for millions of women around the world. The mobile Senographe Essential is built on the company’s Senographe Essential platform, the next-generation of GE’s proven Senographe Full Field Digital Mammography systems.

 

GE Healthcare’s newest mobile unit will feature the largest digital detector in the mammography market, advanced ergonomic design for the technologist, optimized patient comfort and seamless workflow connectivity. The foundation of the Senographe Essential imaging excellence is GE’s advanced digital detector, which delivers the industry's highest Detective Quantum Efficiency (DQE) – the standard for quantifying digital X-ray image quality at low doses.

 

“GE’s goal is to enhance breast care for women worldwide and bring this technology to those who otherwise would not have access to it,” said David Caumartin, general manager of Global Mammography for GE Healthcare. “GE offers customers the broadest portfolio when it comes to breast imaging and the new mobile Essential will be the top of the line mobile product in the market featuring all the proven advantages of our Senographe platform.”